Deng YF, Zhao YQ, Wang L, Cui XS. Understanding the risk factors of hemagglutinase-associated hypofibrinogenemia can improve the prognosis of patients. World J Gastrointest Surg 2025; 17(6): 101206 [DOI: 10.4240/wjgs.v17.i6.101206]
Corresponding Author of This Article
Xian-Shu Cui, Department of Oncology, Affiliated Hospital of Qinghai University, No. 29 Tongren Road, Xining 810000, Qinghai Province, China. m17809711349@163.com
Research Domain of This Article
Hematology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jun 27, 2025; 17(6): 101206 Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.101206
Understanding the risk factors of hemagglutinase-associated hypofibrinogenemia can improve the prognosis of patients
Ying-Fang Deng, Ya-Qi Zhao, Liang Wang, Xian-Shu Cui
Ying-Fang Deng, Xian-Shu Cui, Department of Oncology, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China
Ya-Qi Zhao, Graduate School of Qinghai University, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China
Liang Wang, Department of Gastrointestinal Oncology Surgery, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China
Co-first authors: Ying-Fang Deng and Ya-Qi Zhao.
Co-corresponding authors: Liang Wang and Xian-Shu Cui.
Author contributions: Deng YF and Zhao YQ co-wrote the manuscript, sharing the first authorship; Deng YF and Wang L reviewed the literature; Wang L revised and reviewed the manuscript; Cui XS contributed to the editorial concept and design; all authors have read and approved the final manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xian-Shu Cui, Department of Oncology, Affiliated Hospital of Qinghai University, No. 29 Tongren Road, Xining 810000, Qinghai Province, China. m17809711349@163.com
Received: September 7, 2024 Revised: March 4, 2025 Accepted: March 17, 2025 Published online: June 27, 2025 Processing time: 265 Days and 5.8 Hours
Abstract
We editorialized on this study published by Zou et al. Gastrointestinal bleeding is a common clinical symptom, and hemocoagulase is frequently used to treat hemorrhagic conditions. However, studies have shown that hemocoagulase treatment may induce acquired hypofibrinogenemia, further aggravating the bleeding. Zou et al retrospectively analyzed 109 gastrointestinal bleeding cases to explore the hazards underlying hypofibrinogenemia induced by hemocoagulase, and identified higher total dose of hemocoagulase and female sex, as well as low baseline fibrinogen levels as significant hazards. Consequently, clinicians should be aware of both intrinsic and extrinsic risk factors when using hemocoagulase among this patient population, and remain vigilant for the potential development of hemocoagulase-induced hypofibrinogenemia.
Core Tip: Potential hazards underlying hypofibrinogenemia resulted from hemocoagulase include age, gender, lower baseline fibrinogen levels, route of administration, type of hemocoagulase, cumulative dose, treatment duration, and albumin levels. It's of great significance to understand the above risk factors of hemagglutinase-associated hypofibrinogenemia for improving the prognosis of patients.
